ASX Release
2 November 2026

ASX code: PIQ

Proteomics International Laboratories Ltd launches Share Purchase Plan

HIGHLIGHTS:

- **Proteomics invites eligible shareholders to participate in a Share Purchase Plan (SPP) to raise up to A$5,000,000 (before costs.)**
- **SPP launch follows recent commercial and operational milestones, including the Healius partnership, advancement of the Promarker® portfolio and progress towards US market expansion.**
- **Proceeds designed to fund commercial execution, clinical and reimbursement programs, product launch activities and US market readiness initiatives.**
- **Issue price of $0.10 per Share, which is a 12.2% discount to the 5-day volume weighted average price as at market close on Friday 30 October, 2026.**
- **Subject to Shareholder approval, one free attaching Option will be provided for every Share issued under the SPP, exercisable at $0.15 and expiring two years from the date of issue, to be offered under a separate prospectus, recognising the loyalty and ongoing support of participating shareholders.**
- **SPP Record Date: Friday, 30 October, 2026.**
- **Investors are invited to join a webinar this Wednesday, 4 November, 2026 where CEO, David Morris will discuss recent progress, coming milestones and offer live Q+A.**

Proteomics International Laboratories Ltd (ACN 169 979 971) (**PIQ, Proteomics** or the **Company**), is pleased to announce a Share Purchase Plan (**SPP** or **Offer**) under which Eligible Shareholders (defined below) can subscribe for up to $30,000 worth of new fully paid ordinary shares in the Company (**Shares**) at an issue price of $0.10 per Share (**Price**), to raise up to A$5,000,000 (before costs). Shareholders are invited to participate on the same terms, irrespective of the size of their shareholding and without incurring brokerage or transaction costs,

The SPP Price represents a discount of 12.2% to the volume weighted average market price for the Company's Shares, calculated over the 5 days leading up to market close on Friday, 30 October, 2026 (**5-day VWAP** - A$0.1139), and a discount of 16.7% to the last closing price of the Shares on Friday, 30 October 2026 - A$0.12.

In recent months we have secured our national Healius distribution partnership, commenced the Australian rollout of PromarkerD® and PromarkerEso®, advanced PromarkerEndo® towards launch between January and March 2027, and continued to build the clinical, operational and reimbursement foundations needed to support long-term growth.

In the next phase of commercialisation, the funds raised under the Share Purchase Plan will be directed towards commercial execution, including the Healius rollout, the expected launch of PromarkerEndo®, laboratory capacity, clinical evidence generation to support reimbursement activities and preparations for US market entry.

We are pleased to provide eligible shareholders with the opportunity to participate in this Offer and in recognition of their loyalty and support, each new share issued under the SPP will be accompanied by a free one-for-one attaching option. We believe this is an important stage in the

Company's development and look forward to delivering on the significant opportunities ahead." Proteomics' CEO and Managing Director, David Morris, said:

"Proteomics has entered an exciting new phase. In recent months we have secured our national Healius distribution partnership, commenced the Australian rollout of PromarkerD® and PromarkerEso®, advanced PromarkerEndo® towards launch and continued to build the clinical, operational and reimbursement foundations needed to support long-term growth. With three clinically validated tests targeting significant unmet medical needs and a planned pathway into the US market, we believe the Company is now positioned to translate years of scientific development into commercial outcomes."

Investor webinar invitation – Wednesday, 4 November, 2026 at 12:30pm AEDT / 9:30am AWST

Investors are invited to join a webinar where CEO, David Morris will discuss Proteomics' recent progress and also cover any questions regarding the SPP. All investors are invited to register to attend.

Date: Wednesday, 4 November, 2026

Time: 12:30pm AEDT / 9:30am AWST

Registration: https://us02web.zoom.us/webinar/register/WN_fxm_wxjUTEeQMZIZ8caF0w

Once registered, participants will receive a confirmation email with webinar login details.

Details of the Offer

Participation in the SPP is optional and is open to shareholders who are registered as holders of Shares at 5:00pm (AWST) on Friday, 30 October 2026 (**Record Date**) and whose registered address is in Australia or New Zealand (**Eligible Shareholders**). Shares issued under the SPP will rank equally with existing Shares.

Subject to Shareholder approval, Eligible Shareholders who subscribe for and are issued Shares under the SPP will also receive one (1) free attaching option for every one (1) Share issued to them under the SPP, exercisable at $0.15 and expiring two (2) years from the date of issue (**Option**).

Shares issued under the SPP will be issued under ASX Listing Rule 7.2, Exception 5, pursuant to an SPP offer booklet (**SPP Offer Booklet**). To the extent the number of Shares issued under the SPP exceeds 30% of the Shares on issue as at the date of this announcement, the excess Shares will be issued under the Company's placement capacity under ASX Listing Rule 7.1. The SPP Offer Booklet will be lodged with ASX and despatched to Eligible Shareholders on Wednesday, 4 November, 2026.

The free attaching Options will be offered under a separate options prospectus (**Options Prospectus**) to be lodged with ASIC and ASX at a later date and will require shareholder approval under ASX Listing Rule 7.1, which will be sought at the Company's 2026 Annual General Meeting. An addendum containing additional resolutions will be sent to shareholders as soon as practicable. If shareholder approval is not obtained, no Options will be issued to participants in the SPP.

The Company intends to raise up to A$5,000,000 under the SPP but may, at its absolute discretion, accept oversubscriptions, close the Offer early or scale back applications. Scale back decisions are made by the Board and are final. Any applicable refunds to be made will only be facilitated via electronic funds transfer (EFT) to the Eligible Shareholder's bank account (no refund cheques will be issued). The Offer will not be underwritten.

The directors of the Company who are Eligible Shareholders may participate in the Offer, subject to the ASX Listing Rules.

Use of Funds

The funds raised under the Offer are intended to be applied as follows:

SOURCES	A$M
Opening cash balance (Sept 2026)	1.8
R&D tax incentive	2.0
Other income	0.3
SPP offer proceeds	5.0
Total	**9.1**

USE OF FUNDS	A$M
Research and product development	2.0
Clinical evidence and regulatory	1.6
Laboratory operations and capacity	1.4
Commercial execution and market access	1.6
Corporate costs and working capital	2.5
Total	**9.1**

Note: The above allocation is indicative and assumes the intended amount is raised. The Board reserves the right to vary the way the funds are applied. Totals may not add due to rounding.

Indicative Timetable

EVENT	DATE
Record Date for SPP	Friday, 30 October 2026
Announcement of SPP and lodgment of Appendix 3B	Monday, 2 November 2026
Despatch of SPP Offer Booklet to Eligible Shareholders and release on the ASX platform	Wednesday, 4 November 2026
Opening Date for SPP and cleansing notice	Wednesday, 4 November 2026
Annual General Meeting (including the necessary resolutions to approve the issue of the Options)	Friday, 20 November 2026
Lodgement of Options Prospectus with ASIC and ASX	Friday, 20 November 2026
Closing Date for SPP	Wednesday, 25 November 2026
Announcement of results of SPP	Friday, 27 November 2026
Issue of new Shares under the SPP and lodgment of Appendix 2A	Monday, 30 November 2026

EVENT	DATE
Subject to shareholder approval, issue of Options under the Options Prospectus to SPP participants and lodgment of Appendix 3G	Monday, 30 November 2026

Note: The above dates are indicative only. The Company may vary the dates and times of the Offer without notice. Accordingly, Eligible Shareholders are encouraged to submit their applications as early as possible.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

For further information please contact:

David Morris
CEO and Managing Director
+61 8 9389 1992 | enquiries@proteomicsinternational.com

Jane Lowe
Investor Relations, IR Department
+61 411 117 774 | jane.lowe@irdepartment.com.au

Further information about the Company is available on the Company's website (see www.proteomicsinternational.com).

About Proteomics International Laboratories Ltd

Proteomics International is a Perth-based medical technology company specialising in proteomics, the study of proteins and their functions. The Company develops precision diagnostic tests and provides specialist bioanalytical services to improve the detection and management of disease.

Forward Looking Statements and Disclaimers

This announcement is for information purposes only and does not constitute a prospectus or prospectus equivalent document. It is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer to purchase or otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, nor shall there be any offer, sale, issuance or transfer of securities in any jurisdiction in contravention of any applicable law.

This announcement contains forward looking statements. Forward looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "forecast", "believe", "plan", "estimate", "expect" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions.

The forward looking statements in this announcement are based on current expectations, estimates, forecasts and projections about the Company and the industry in which it operates. They do, however, relate to future matters and are subject to various inherent risks and uncertainties. Actual events or results may differ materially from the events or results expressed or implied by any forward looking statements. The past performance of the Company is no guarantee of future performance.

Neither the Company nor any of its directors, officers, employees, agents or contractors makes any representation or warranty (either express or implied) as to the accuracy or likelihood of fulfilment of any forward looking statement, or any events or results expressed or implied in any forward looking statement, except to the extent required by law.

You are cautioned not to place undue reliance on any forward looking statement. The forward looking statements in this announcement reflect views held only as at the date of this announcement.